Featured Research

from universities, journals, and other organizations

Mayo Clinic Reports New Option For Patients With Metastatic Melanoma

Date:
January 4, 2006
Source:
Mayo Clinic
Summary:
Patients with metastatic melanoma (MM) have new hope, says a recently published study by Mayo Clinic Cancer Center. The study, which shows the combination of paclitaxel and carboplatin (PC) appears to be effective for MM when traditional treatments have failed, is in this month's issue of Cancer.

Patients with metastatic melanoma (MM) have new hope, says a recently published study by Mayo Clinic Cancer Center. The study, which shows the combination of paclitaxel and carboplatin (PC) appears to be effective for MM when traditional treatments have failed, is in this month's issue of Cancer.

"Melanoma is unfortunately one of the few cancers that has become more common over the last few decades, and when it becomes metastatic, there are very few treatment options," says Ravi Rao, M.B.B.S., Mayo Clinic oncologist and lead investigator of the study. "This is a good step towards better treating this cancer. We hope to continue to find treatment options that extend and improve life expectancy for patients." This study appears to have found one such option, with nearly half of the patients that received PC experiencing a clinical benefit of stable disease (19 percent) or tumor size reduction (26 percent).

The National Cancer Institute reports a 2.4 percent increase in the incidence of melanoma between 1992 and 2002. New cases are diagnosed in about 60,000 people each year in the United States, and almost 8,000 die because of metastasized melanoma. Because they know that most therapies provide palliative as opposed to curative options, researchers at Mayo Clinic Cancer Center consider developing more effective curative treatment options to be a priority.

Dr. Rao and his co-investigators examined the records of 31 MM patients at Mayo Clinic who were treated with the PC combination between March 2003 and January 2005. These patients had previously received (and failed) an average of two treatments, including vaccine/immunotherapy. Interestingly, the researchers found that this combination benefited even those patients in whom temozolomide (currently the most commonly used chemotherapy drug for melanoma) failed.

Because the data was collected from the records of patients treated previously and was not part of a set treatment regimen, the schedule and dosage of PC varied. However, the researchers believe that using the drugs weekly (compared to once every three weeks) makes the combination more tolerable, and the researchers prefer that option.

"Other recent studies in the U.S. and Germany looking at combinations that included PC, indicated that there is some clinical benefit from this combination," says Dr. Rao. "Combined with our results, we believe that the PC combination truly has a beneficial role, especially for patients who've had poor results from other treatment options.

"However, this study is retrospective in nature, and further studies are needed to fully understand the impact of this combination on the survival of patients with metastatic melanoma," he says. Dr. Rao also notes that several additional trials using this drug combination are being planned, including some at the Mayo Clinic Cancer Center.

Others involved in the study included Shernan Holtan, M.D.; James Ingle, M.D.; Gary Croghan, M.D., Ph.D.; Lisa Kottschade; Edward Creagan, M.D.; Judith Kaur, M.D.; Henry Pitot, M.D.; and Svetomir Markovic, M.D., Ph.D.

###

For more information on melanoma treatment and research at Mayo Clinic, go to www.mayoclinic.org/melanoma.



Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Mayo Clinic Reports New Option For Patients With Metastatic Melanoma." ScienceDaily. ScienceDaily, 4 January 2006. <www.sciencedaily.com/releases/2006/01/060103184118.htm>.
Mayo Clinic. (2006, January 4). Mayo Clinic Reports New Option For Patients With Metastatic Melanoma. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/01/060103184118.htm
Mayo Clinic. "Mayo Clinic Reports New Option For Patients With Metastatic Melanoma." ScienceDaily. www.sciencedaily.com/releases/2006/01/060103184118.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins